R&D at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's R&D?
- Arbutus Biopharma Corporation (ABUS) reported R&D of $4.12M in Q1 2026.
- How has Arbutus Biopharma Corporation's R&D changed year-over-year?
- Arbutus Biopharma Corporation's R&D decreased by 54.0% year-over-year, from $8.96M to $4.12M.
- What is the long-term trend for Arbutus Biopharma Corporation's R&D?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's R&D has grown at a -21.2% compound annual growth rate (CAGR), from $65.5M to $25.24M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.